This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Subbiah, V. et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med. https://doi.org/10.1038/s41591-023-02321-8 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. ROAR brings in a new histology-agnostic approval for rare cancers. Nat Rev Clin Oncol 20, 425 (2023). https://doi.org/10.1038/s41571-023-00778-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00778-7